High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo
Open Access
- 1 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1), ofad023
- https://doi.org/10.1093/ofid/ofad023
Abstract
By the end of the third wave of the COVID-19 epidemic (May – October 2021), only 3,130 out of the 57,268 confirmed cases of coronavirus disease 2019 (COVID-19) in the Democratic Republic of Congo (DRC) were reported in Kongo Central. This province, and especially its capital city Matadi has essential trade and exchanges with Kinshasa, the epicenter of the COVID-19 epidemic in DRC. Kinshasa accounted for 60.0% of all cases during the same period. The true burden of COVID-19 in Matadi is likely underestimated. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and associated risk factors after the third wave in Matadi. We conducted a prospective population-based cross-sectional study in October 2021. Consenting participants were interviewed and tested using an ELISA commercial kit. We applied univariable and multivariable analysis to evaluate factors associated with seropositivity and adjusted the seroprevalence for the test kit performance. We included 2,210 participants from 489 households. Female participants represented 59.1%. The median age was 27 years (interquartile range 16–45 years). The crude SARS-CoV-2 seroprevalence was 82.3%. Age was identified as the main risk factor as younger age decreased the seropositivity odds. Accounting for clustering at the household level increased the seroprevalence to 83.2%. The seroprevalence increased further to 88.1% (95% CI 86.2–90.1%) after correcting for the laboratory test kit performance. The SARS-CoV-2 seroprevalence was very high, contrasting with reported cases. Evidence generated from this population-based survey remains relevant in guiding the local COVID-19 response, especially vaccination strategies.Funding Information
- Japan International Cooperation Agency
This publication has 32 references indexed in Scilit:
- Seroprevalence surveys in sub-Saharan Africa: what do they tell us?The Lancet. Global Health, 2021
- Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample surveyThe Lancet. Global Health, 2021
- Evolution of antibody immunity to SARS-CoV-2Nature, 2021
- SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study2020
- Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral ImmunityImmunity, 2020
- Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit ErrorAmerican Journal of Epidemiology, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- On the importance of population-based serological surveys of SARS-CoV-2 without overlooking their inherent uncertaintiesPublic Health in Practice, 2020
- Molecular identification of Plasmodium species in symptomatic children of Democratic Republic of CongoMalaria Journal, 2018